Table 2 Toxicity and hospitalisation during CAPOX treatment
CAPOX 2000 ( n =200) | CAPOX 1700 ( n =200) | |||||||
|---|---|---|---|---|---|---|---|---|
Toxicity | G1 | G2 | G3 | G4 | G1 | G2 | G3 | G4 |
Diarrhoea | 60 (30%) | 16 (8%) | 40 (20%) | 1 (0.5%) | 40 (20%) | 24 (12%) | 35 (17.5%) | 3 (1.5%) |
Lethargy | 47 (23.5%) | 11 (5.5%) | 15 (7.5%) | 0 (0%) | 56 (28%) | 34 (17%) | 33 (16.5%) | 1 (0.5%) |
Hand foot syndrome | 23 (11.5%) | 18 (9%) | 13 (6.5%) | 0 (0%) | 21 (10.5%) | 8 (4%) | 13 (6.5%) | 0 (0%) |
Stomatitis | 22 (11%) | 5 (2.5%) | 0 (0%) | 0 (0%) | 22 (11%) | 5 (2.5%) | 2 (1%) | 0 (0%) |
Peripheral neuropathy | 97 (48.5%) | 16 (8%) | 12 (6%) | 0 (0%) | 109 (54.5%) | 24 (12%) | 10 (5%) | 0 (0%) |
Chest paina | 0 (0%) | 0 (0%) | 6 (3%) | 0 (0%) | 4 (2%) | 0 (0%) | 4 (2%) | 0 (0%) |
Laboratory data | ||||||||
Neutropenia | 7 (3.5%) | 12 (6%) | 16 (8%) | 3 (1.5%) | 7 (3.5%) | 8 (4%) | 7 (3.5%) | 0 (0%) |
Elevated bilirubin | 77 (38.5%) | 37 (18.5%) | 5 (2.5%) | 0 (0%) | 47 (23.5%) | 27 (13.5%) | 5 (2.5%) | 0 (0%) |
Elevated ALT | 87 (43.5%) | 16 (8%) | 3 (1.5%) | 0 (0%) | 55 (27.5%) | 21 (10.5%) | 5 (2.5%) | 0 (0%) |
Elevated alkaline phosphatase | 63 (31.5%) | 12 (6%) | 2 (1%) | 0 (0%) | 77 (38.5%) | 11 (10.5%) | 4 (2%) | 0 (0%) |
Hospitalisation rate due to grades 3 out of 4 toxicities | ||||||||
Yes | 26 (13%) | 21 (10.5%) | ||||||
No | 174 (87%) | 179 (89.5%) | ||||||
Length of hospitalisation | ||||||||
Mean | 4.91 days | 10.53 days | ||||||
s.d. | 4.73 days | 9.99 days | ||||||
Median | 3 days | 6.5 days | ||||||
Range | 1–21 days | (1–39 days) | ||||||
Deaths during hospital admission | 0 | 2 | ||||||
